AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.
A major cancer research network proposes tracking individual tumor cells in blood alongside genetic and metabolic data using AI, potentially revealing how cancers spread and resist treatment.
This framework paper from Japan's SCRUM-MONSTAR consortium—one of the largest pan-cancer molecular profiling initiatives globally—proposes extending the platform to systematic circulating tumor cell profiling integrated with single-cell CTC transcriptomics, metabolomics, and AI-enabled clinical interpretation. The goal is to develop biomarker-guided anti-metastatic trials targeting functional metastatic plasticity programs (particularly adherent-to-suspension transition) that remain invisible to ctDNA-only approaches.
What the study was
- Study design
- platform_description_framework_paper
- Population
- Pan-cancer patients enrolled in SCRUM-MONSTAR registry (framework paper; no specific N reported for current study)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Int J Clin Oncol
Why it surfaced
Vision framework from Japan's leading pan-cancer precision oncology consortium proposing an AI-integrated CTC profiling ecosystem to identify and therapeutically target functional metastatic plasticity—addresses a fundamental limitation of current liquid biopsy approaches in anti-metastatic drug development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.